NantOmics Announces Study Showing Signature Analysis that Reveals Three Distinct Classifications of Skin Cancer Known as Sebaceous Carcinoma

May 21, 2018

Research published on May 14 in the peer-reviewed journal Nature Communications shows for the first time three distinct classifications of sebaceous carcinoma, a rare and sometimes deadly form of skin cancer.

Culver City, CA – May 21, 2018 – NantOmics, LLC, the leader in molecular analyses and a member of the NantWorks ecosystem of companies, announced today the publication of peer-reviewed research  defining for the first time three distinct classifications of sebaceous carcinoma, a rare and sometimes deadly former of skin cancer. 

A study published on May 14 in the journal Nature Communications shows that a signature analysis reveals three clinically distinct classes of sebaceous carcinoma. The research offers fresh insights into how to treat the disease and adds more data to the concept that different mutational processes drive cancers that originate in the same location but are clinically distinct.

Using the technology that drives NantHealth Inc’s (NASDAQ: NH) GPS Cancer® platform, NantOmics scientists performed tumor-normal DNA sequencing and RNA sequencing on tissue samples from 32 patients with sebaceous carcinoma, revealing that the cell of origin and mutation patterns defined three clinically distinct classes. These explain both cancer ontogeny and clinical course.

“This is the first time that we have been able to define sebaceous carcinoma into distinct molecular classifications with defined mutational signature profiles,” said Dr. Shahrooz Rabizadeh, Chief Scientific Officer at NantOmics. “We believe that our findings and the classifications have significant implications on patient treatment.”

Dr. Patrick Soon-Shiong, CEO and founder of NantOmics said the research reiterated the importance of no longer treating cancer by anatomy, but based on biology.

“This research has helped to decode signatures that are based on the diseases molecular profile,” Soon-Shiong said. “Beyond treatment implications, this shows the absolute importance of looking at cancer treatment from a biological perspective.”  

Nature Communications is a peer-reviewed, open-access journal that publishes research on all areas of natural sciences. Papers published by the journal are considered to represent important advances in their fields of research. 

Other highlights from the paper:

  • A UV-damage signature classification predominates in ten of the 32 samples.
  • Nine of the samples are classified by microsatellite instability (MSI) profiles, which has been shown to be responsive to and is approved for pembrolizumab (Keytruda®) use.
  • The third classification, pauci-mutational sebaceous carcinoma has a more varied signature, but half of which shared a similar mutation pattern in ZNF750 transcription factor in this study.
  • Neoepitope analysis identified a subset of patients with highly clonal mutation burden that may be most responsive to immunotherapy, and may potentially be strong candidates for treatment with neoepitope vaccines.

About NantOmics, LLC

NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular testing company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter@DrPatSoonShiong.

About NantHealth, Inc.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth's unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissue and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system that integrates our unique molecular profiling solution, software and hardware. Our system infrastructure collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources to continuously improve decision-making and optimize our clinical pathways and decision algorithms over time. For more information please visit http://www.nanthealth.com/.

 About GPS Cancer®

GPS Cancer® is a unique, comprehensive test available through NantHealth. GPS Cancer integrates tumor/normal DNA and RNA sequencing, with enhanced expression analysis and bioinformatics of complex biologic pathway systems, providing oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer testing is conducted in CLIA-certified and CAP-accredited laboratories. For more information, visit www.gpscancer.com.

NANT MEDIA CONTACT
Jen Hodson
jhodson@nantworks.com
562-397-3639

Henry Jackson
cj@nantworks.com
310-486-8908


 

SNN: Breakthrough Cancer Treatment Targets Each Patient's Unique Tumor

February 17, 2017

SNN: Breakthrough Cancer Treatment Targets Each Patient’s Unique Tumor

Genos Names Four Research Partners, Launches Sequencing Platform

December 16, 2016

a GenomeWeb staff reporter
NEW YORK (GenomeWeb) – Consumer genomics firm Genos announced yesterday named four of its research partners, which are using the company's newly launched whole-exome sequencing platform in various projects and clinical studies.

For $499, individuals can have their exomes sequenced from a saliva sample, then explore their genetic profiles online. Customers can also choose to share their data with academic and commercial researchers in exchange for compensation.
"Cultivating a community around genomics research promises to illuminate the genetic underpinnings of the human condition, including finding cures to our most elusive diseases," Genos Co-Founder and CEO Mark Blumling said in a statement. "It also engages people in their own healthcare like never before. To realize this great potential, we must remove the barriers to accelerating research, and the only way to do that is by putting consent and control over personal genomics data where it belongs — in the hands of individuals."

As part of the launch, Genos said that its platform is being used by several collaborators including NantBioScience, which is using it in a Phase I clinical trial for lymphoma and a Phase I study of a breast cancer vaccine; NantKwest, which is using the technology in a phase II study of a treatment for Merkel cell carcinoma; the Broad Institute as part of research into the genetic variants of the prion protein; and the Utah Foundation for Biomedical Research in a project looking at genetic variances of common neurological and psychiatric disorders to guide treatment.

"It is extraordinary that Genos will offer us an unbiased way to find mutations in genes dealing with autism and other neurodevelopment conditions, and we look forward to seeing what we are able to discover by using this platform," Utah Foundation for Biomedical Research investigator Gholson Lyon said in the statement.

Launch of the Genos platform comes about a month after the company raised $6 million from NantOmics, a subsidiary of NantWorks.

 

The CLIA certification and CAP accreditation ensures the highest quality test results from the NantOmics lab to help improve cancer outcomes and will support the Cancer Cancer Breakthroughs 2020 mission in its war on cancer

CULVER CITY, Calif. – April 19, 2016 – NantOmics, LLC, the leader in molecular diagnostics and member of the NantWorks ecosystem of families, today announced that its laboratories have been certified by the U.S. Department of Health and Human Services' Centers for Medicare & Medicaid Services under the Clinical Laboratory Improvement Acts (CLIA) of 1988, and has been accredited by the College of American Pathologists (CAP). As the nation’s first and only CLIA-certified, CAP-accredited laboratories to perform whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics—all in one comprehensive test—today’s announcement exemplifies the highest quality standard delivered by NantOmics to ensure accuracy, reliability, and timeliness of patient test results.

“The approval by the CLIA and CAP regulatory organizations provides the analytic validity of the laboratories to perform molecular diagnostic tests and provides the catalyst to dramatically change the current paradigm of cancer care by bringing the promise of 21st century precision medicine to cancer patients today,” said Shahrooz Rabizadeh, chief scientific officer of NantOmics. “Clinicians utilizing our comprehensive test will have the assurance that the test results will be reliable and of the highest quality.”

The CLIA and CAP programs regulate laboratories that test patient specimens to ensure accurate and reliable test results are produced in addition to helping laboratories achieve the highest standards of excellence to positively impact patient care.

“Novel cancer immunotherapies, combination therapies and other investigational therapies that can harness the power of the patient’s own immune system are the path to winning the cancer war,” said Dr. Patrick Soon-Shiong, CEO of NantOmics. “The ability to perform whole genome sequencing, RNA sequencing and quantitative proteomics—in a CLIA-certified, CAP-accredited lab—underscores the high-quality and reliability needed to understand a patient’s biology, and marks a significant milestone for the Cancer Breakthroughs 2020 program’s mission to win the war against cancer.”

About CAP accreditation: What does it mean to be CAP-accredited?

The College of American Pathologists (CAP), the leading organization of board-certified pathologists, serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.

CAP's Laboratory Accreditation Program is widely recognized as the 'gold standard' and has served as a model for various federal, state, and private laboratory accreditation programs throughout the world.

Its inspection program is internationally recognized and the only one of its kind that utilizes teams of practicing laboratory professionals as inspectors. Designed to go well beyond regulatory compliance, the program helps laboratories achieve the highest standards.

About CLIA certification: What does it mean to be CLIA-certified?

The Clinical Laboratory Improvement Amendments (CLIA) establish quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test was performed.

CLIA specifies quality standards for proficiency testing (PT), patient test management, quality control, personnel qualifications and quality assurance for laboratories performing moderate and/or high complexity tests.

About NantOmics

NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About Cancer Breakthroughs 2020

The Cancer Breakthroughs 2020 Program is the nation's most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational initiative to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, visit http://www.CancerBreakthroughs2020.org.

Media Contact
Jen Hodson
NantWorks
jhodson@nantworks.com
562-397-3639

 

NantOmics Announces Presentations at the 2015 San Antonio Breast Cancer Symposium

December 09, 2015

CULVER CITY, Calif.--(BUSINESS WIRE)--NantOmics, a leading molecular diagnostic company and a member of the NantWorks ecosystem of companies, today announced that three posters describing the molecular profiling of tumors from patients enrolled in five clinical trials will be presented at the 2015 San Antonio Breast Cancer Symposium (SABCS), being held December 8 to 12, 2015 in San Antonio, Texas.

“NantOmics is committed to providing oncologists with actionable information through comprehensive molecular analyses,” said Shahrooz Rabizadeh, Chief Scientific Officer at NantOmics, "Our data at SABCS showcase the significant benefits of analyzing the combination of DNA sequencing and RNA sequencing, together with quantitative proteomics to help bring novel and more effective personalized treatments to patients with cancer.”

Details of the presentations are listed below and available on the SABCS website:

  • Title: “Quantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial”
  • Poster Session: P3-07-08, Thursday, December 10, 2015, 5 p.m. – 7 p.m.
  • Location: Exhibit Hall A and B
  • Title: “Integrating whole exome sequencing data with RNA-seq and quantitative proteomics to better inform clinical treatment decisions in patients with metastatic triple negative breast cancer”
  • Poster Session: P6-05-08, Saturday, December 12, 2015, 7:30 a.m. – 9 a.m.
  • Location: Exhibit Hall C
  • Title: “Integrating whole genome sequencing data with RNA-seq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients”
  • Poster Session: P6-04-14, Saturday, December 12, 2015, 7:30 a.m. – 9 a.m.
  • Location: Exhibit Hall C
     

About NantOmics

NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analysing both normal and tumour cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud‐based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real‐time, and correlating proteomic pathway analysis with quantitative multi‐plexed protein expression analysis from the same micro‐dissected tumour sample used for genomic analysis.For more information, please visit www.nantomics.com and follow Dr. Soon‐Shiong on Twitter @solvehealthcare.

About NantWorks

NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobileHealth, NantOmics, NantBio, NantCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operates at the nexus of innovation and infrastructure.

The core mission of NantWorks is convergence and a systems approach to human biology: to develop and deliver a diverse range of technologies that accelerates innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically and proteomically -informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics for life threatening diseases such as Cancer, Infectious Diseases and Alzheimer’s. For more information please visit www.nantworks.com and follow Dr. Soon-Shiong on Twitter @solvehealthcare.

View source version on businesswire.com.


NantOmics Acquires Oncoplex Diagnostics, An Accredited Proteomics Diagnostic Laboratory

LOS ANGELES, CA., September 10, 2015

LOS ANGELES – (Business Wire) – NantOmics, a leading molecular diagnostic company and a member of the NantWorks ecosystem of companies, today announced that it has acquired the remaining shares of privately owned OncoPlex Diagnostics, an accredited clinical laboratory focused on testing tumor cell proteins using mass spectrometry analysis. Financial terms of the transaction were not disclosed.

OncoPlex was funded by Dr. Soon‐Shiong's entities since 2008 and the strategic benefits of completing the acquisition include a CAP‐accredited, CLIA‐certified laboratory, technical expertise and a significant expansion of NantOmics’s portfolio of molecular diagnostic tests. Headquartered in Rockville, Maryland, OncoPlex provides comprehensive‐profiling services of patients' tumors intended to enable more informed and better treatment decisions. The company’s proprietary quantitative proteomic clinical assays have been validated in multicenter studies and its novel multiplexed method is one of the most sensitive and specific detection tools available in the clinical laboratory today.

“OncoPlex brings to NantOmics unique, proprietary technology that provides clinically relevant and highly accurate quantitative test results for patients with cancer,” said Dr. Patrick Soon‐Shiong, physician scientist, biotechnology entrepreneur and NantWorks founder. “With this integration, we have added state‐of‐the‐art discovery tools and a complementary array of molecular diagnostic services and tests. More importantly, we have enhanced our ability to deliver patient‐specific pan‐omic information and, ultimately, improve disease diagnosis and therapy. We are now positioned to provide whole genomic sequencing, transcriptomics, predictive proteomics and quantitative proteomics...the most comprehensive diagnostic platform for cancer patients in the world today."

“By combining DNA sequencing, RNA sequencing and protein expression utilizing mass spectrometry, NantOmics can now offer expanded testing capabilities that provide a broader and more comprehensive picture of a patient’s unique tumor biology,” said Todd Hembrough, Ph.D., Chief Scientific Officer and formerly vice president of research and development at OncoPlex. “Moreover, NantOmics has further established itself as a leader in comprehensive molecular diagnostic testing, with the ability to provide more useful information to medical oncology professionals.”

About OncoPlex Diagnostics

OncoPlex Diagnosticsis the only CAP‐accredited, CLIA‐ertified laboratory with the unique and proprietary capability to solubilize tumor cell proteins from FFPE tissue for quantitation by mass spectrometry analysis. With next generation sequencing analysis also available from the same sample, this innovative approach allows for multiple targeted proteomic and genomic results from a biopsy specimen. For more information, please visit www.oncoplexdx.com.

About NantOmics

NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analysing both normal and tumour cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud‐based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real‐time, and correlating proteomic pathway analysis with quantitative multi‐plexed protein expression analysis from the same micro‐dissected tumour sample used for genomic analysis.For more information, please visit www.nantomics.com and follow Dr. Soon‐Shiong on Twitter @solvehealthcare.

View source version on businesswire.com.